The effects of Levodopa on autonomic nervous system (ANS) were investigated through the measurement of blood pressure (BP) and heart rate (HR) variability in 15 de novo parkinsonian who never received dopaminergic drugs. BP and HR were obtained using digital photoplethysmography in supine and standing positions. Measurements were achieved 90 min after administration, in a double blind cross-over way, of placebo or levodopa (200 mg) + benserazide (50 mg). Spectral analysis was performed using fast Fourier transformation (FFT) on 512 consecutive SBP and HR values. Spectral modulus was integrated for calculation of total spectra and of low frequency (LF: 66-129 mHz) or high frequency band (HF: respiratory frequency ± 50 mHz). After placebo, orthostatism was followed by a significant increase in BP and HR whereas relative variabilities in LF and HF remained unchanged.
Several experimental studies have shown that antiparkinsonian drugs affect cardiovascular regulation. Levodopa plus dopa-decarboxylase inhibitor, decreases blood pressure (BP) both in humans (1, 2) and in animals (3, 4) by acting at peripheral and/or central levels (5). Despite the large number of studies, no clear conclusions can be made concerning the effects of levodopa on autonomic nervous system (ANS). This is due to the heterogeneity of severity or duration of the disease which are correlated to the incidence of autonomic dysfunction (6, 7) but also to the lack of reliability of the methods used to investigate sympathetic or parasympathetic function.
Spectral analysis of BP and HR is a new simple technique to investigate ANS activity (8-10). Fast Fourier transformation (FFT) allows the identification of BP and HR oscillations occurring at 66-129 mHz or synchronous to respiration reflecting respectively sympathetic and parasympathetic activity.
In the present study, we investigated, in a double-blind cross-over way versus placebo, the effects of acute levodopa + carbidopa administration on BP and HR variability in supine position and after 15 min standing in 15 parkinsonian (PD) patients never previously treated with dopaminomimetic drugs.
Patients and Methods
Patients and BP and HR Measurements Fifteen de novo PD patients (7 men and 8 women), mean age (61 ± 4 years), duration of disease (4 ± 1 years), Hoehn and Yahr stage 1 or 2, gave informed consent and were included in the study. They were all selected according to the UK brain bank criteria and had never been treated by dopaminergic drugs. None presented orthostatic hypotension or was taking drugs able to modify ANS activity. BP and HR were measured using digital photoplethysmography with Finapres°. The cuff was placed on the second phalang of the third finger of the dominant hand. A Dinamap was positioned on the opposite side in order to standardize the measures. Data form Finapres were digitalized at 500 Hz and stored. FFT was performed on series of 512 points on SBP and HR using Anapres software (Notocord systems, France). Energy of total spectrum and of 2 bands (LF: 70-130 mHz and HF: respiratory frequency ± 50 mHz) were calculated by integration of the spectral modulus.
General Procedure Recordings were obtained at similar times on 2 consecutive days after a 30 min rest in supine position 
Discussion
We selected only PD patients who never previously received antiparkinsonian drugs in order to really investigate the effects of acute levodopa administration. Several studies have investigated the effects of levodopa on cardiovascular responses. However, they were only performed in chronically treated patients deprived for some hours or their regular treatment (11-14). The dose administered was sufficient to induce motor effect in most patients but failed to induce symptomatic orthostatic hypotension (data not shown). Levodopa reduced SBP in resting position and this was not associated with an increase in HR. The lack of tachycardia was previously reported and suggest that levodopa action on BP is from central origin (5). Despite its hypotensive action, levodopa does not impair cardiovascular adaptation to standing. This in accordance with results obtained in patients deprived of levodopa for 24 h. As previously reported (5) the sole effect of levodopawas a decrease of SBP which can be explained by its antiparkinsonian effects.
Spectral analysis is reproductible enough to allow to detect minimal changes in ANS in reduced S176 Hypertens Res Vol. 18, Suppl. I (1995) (16) . Levodopa failed to modify spectral parameters. This is unlikely to be due to limitations of the method or to a too small dose. Another explanation is that levodopa does not interfere with ANS activity but modifies BP through an action on central dopaminergic system involved in BP regulation.
In conclusion, these results suggest 1) the occurrence of autonomic dysfunction even in early stages of PD and 2) the effects of levodopa on BP do not depend on a direct effect on baroreflex mechanisms. 
